Evidence map›Paper›PMID 24464308›Full record

ReviewCurrent cardiology reports2014

Current state of anticoagulants to treat deep venous thrombosis.

Timothy Vo, Sara Vazquez, Matthew T Rondina

Abstract readReview
In one paragraph

Review in Current cardiology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Timothy VoSUNY Upstate Medical University, Syracuse, NY, 13210, USA.
Sara Vazquez
Matthew T Rondina

Funding

Novel Platelet Functions in Sepsis and Venous ThromboembolismK23HL092161 · NHLBI · UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2009 to 2013
$775k
The Regulation of Inflammatory Gene Responses in AgingR03AG040631 · NIA · UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2011 to 2012
$149k
NHLBI NIH HHS K23 HL092161NHLBI NIH HHS K23HL092161NIA NIH HHS R03 AG040631NIA NIH HHS R03AG040631
6 · The paper itself

Abstract

Anticoagulation remains the cornerstone of treatment in patients with deep vein thrombosis (DVT). While parenteral anticoagulants and oral vitamin K antagonists (e.g., warfarin) have been used for many decades, the recent development of novel oral anticoagulants have provided clinicians with an expanding set of therapeutic options for DVT. This review summarizes the pharmacology and clinical trial results of these new oral anticoagulants. Several practical considerations to the use of these oral anticoagulants including issues related to adherence, monitoring, and reversal are also discussed.

Indexed as

AnticoagulantsBenzimidazolesbeta-AlanineDabigatranHumansMedication AdherenceMorpholinesPatient SelectionPyrazolesPyridinesPyridonesRivaroxabanThiazolesThiophenesVenous ThrombosisAnticoagulantsapixabanBenzimidazolesbeta-AlanineDabigatranedoxabanMorpholinesPyrazolesPyridinesPyridonesRivaroxabanThiazolesThiophenes

Identifiers

PMID24464308
PMCPMC3954648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.